Research programme: Axl receptor tyrosine kinase inhibitors - Astex Pharmaceuticals

Drug Profile

Research programme: Axl receptor tyrosine kinase inhibitors - Astex Pharmaceuticals

Alternative Names: Axl-9; SGI-AXL-277

Latest Information Update: 19 Apr 2012

Price : $50

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 15 Mar 2012 Discontinued for Haematological malignancies in USA (unspecified route)
  • 23 May 2007 Pharmacodynamics data from a Preclinical trial in Cancer presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007)
  • 01 Dec 2006 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top